Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.

Literature DB >> 1386383

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.

J L Montastruc, O Rascol, J M Senard, A Rascol.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1992 PMID： 1386383 PMCID： PMC489186 DOI： 10.1136/jnnp.55.7.630-a

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

× No keyword cloud information.

6 in total

1. Excitatory amino acid antagonists and Parkinson's disease.

Authors: J A Girault; S Halpain; P Greengard
Journal: Trends Neurosci Date: 1990-08 Impact factor: 13.837

2. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.

Authors: T Klockgether; L Turski
Journal: Ann Neurol Date: 1990-10 Impact factor: 10.422

3. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.

Authors: C Carter; J Benavides; P Legendre; J D Vincent; F Noel; F Thuret; K G Lloyd; S Arbilla; B Zivkovic; E T MacKenzie
Journal: J Pharmacol Exp Ther Date: 1988-12 Impact factor: 4.030

4. Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines.

Authors: I J Reynolds; R J Miller
Journal: Mol Pharmacol Date: 1989-11 Impact factor: 4.436

5. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.

Authors: L Turski; K Bressler; K J Rettig; P A Löschmann; H Wachtel
Journal: Nature Date: 1991-01-31 Impact factor: 49.962

6. Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex.

Authors: C J Carter; K G Lloyd; B Zivkovic; B Scatton
Journal: J Pharmacol Exp Ther Date: 1990-05 Impact factor: 4.030

6 in total

9 in total

Review 1. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors: Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal: Neuropsychopharmacology Date: 2011-09-28 Impact factor: 7.853

Review 2. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.

Authors: Laetitia Mony; James N C Kew; Martin J Gunthorpe; Pierre Paoletti
Journal: Br J Pharmacol Date: 2009-07-08 Impact factor: 8.739

Review 3. New directions in the drug treatment of Parkinson's disease.

Authors: J L Montastruc; O Rascol; J M Senard
Journal: Drugs Aging Date: 1996-09 Impact factor: 3.923

4. N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease.

Authors: J Kornhuber; P Riederer
Journal: J Neurol Neurosurg Psychiatry Date: 1993-04 Impact factor: 10.154

Review 5. Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors: Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal: CNS Neurol Disord Drug Targets Date: 2009-12 Impact factor: 4.388

6. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?

Authors: S Brooks; S Kaur; B S Starr; M S Starr
Journal: J Neural Transm (Vienna) Date: 1996 Impact factor: 3.575